Overview

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Status:
Completed

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.

Phase:

Phase 1

Details

Lead Sponsor:

TG Therapeutics, Inc.

Treatments:

Chlorambucil
Obinutuzumab